Malignant Hematology
Name the BiTes approved for r/r DLBCL
Epcoritamab and Glofitamab
This is the target for Telistotuzumab vedotin
c-MET (IHC >= 25%)
Choice of regimen and trial name in esophageal adenocarcinoma in perioperative setting.
FLOT - based on ESOPEC trial
A 52 year old female underwent prophylactic complete bilateral mastectomy for BRCA1 mutation and pathology of both breast revealed DCIS in left breast 7 mm, <2 mm from the closest margin, ER 80%, PR 70%, grade 2. How long should the adjuvant endocrine treatment be given?
Not required.
Lymphoma most commonly having t(11;14)
Mantle Cell Lymphoma
Neoadjuvant treatment modality in resectable superior sulcus tumor - T3/T4 N0/N1 disease
ChemoRT
This regimen and trial is standard of care for cis eligible muscle invasive bladder cancer.
Cis Gem Durva - Niagara trial
These PARPis are approved in Breast cancer.
Olaparib, Talazoparib
Before starting this drug, need to send RBC genotyping
Daratumumab
In which cancer Masaoka staging used
Thymoma
This TKI is used in patients with unresectable/metastatic GIST with PDGFRA exon 18 mutation (D842V).
Avapritinib
First line for de novo metastatic TNBC with NGS showing tp53 mutation, PDL1 8%, TMB 7 muts/mb.
Single agent chemo - taxane, anthracyclines or platinum.
AML mutation confers a favorable prognosis only in the absence of FLT3-ITD
NPM1 mut
These are the mutation we look for if a patient is undergoing resection of stage II NSCLC
ALK, EGFR 21 L858R and Exon 19 del
A 65 year old male with recently diagnosed prostate cancer, which is invading seminal vesicle and has node enlargement on scan, majority cores showing 4+5, PSA 37 ng/ml. He is not a candidate for surgery. RT is preferred modality of treatment. This additional systemic treatment is necessary?
Abiraterone (2 years) plus ADT (3 years)
A 58 year old female with BRCA 2 mutation developed early stage HER2 positive breast cancer s/p neoadjuvant systemic treatment, lumpectomy with sentinel node dissection and found to have some residual disease. Plan to start T-DM1. Which PARPi would be recommended for her BRCA mutation for adjuvant treatment?
None.
This mutation predicts response to venetoclax in AML due to mitochondrial dependence.
IDH1/2
Perioperative Durva FLOT did not show benefit in this subgroup of gastric and GEJ adenocarcinoma based on histology.
Diffuse Subtype
A 60 year old female with pT1a grade 1 ER+ HER2- IDC s/p lumpectomy with no sentinel lymph node biopsy. Should the patient receive partial breast RT/Whole breast RT?
Whole breast.